CHICAGO--(BUSINESS WIRE)--Dr. David Agus, a world-renowned cancer specialist, has joined Tempus, a technology company focused on helping doctors personalize cancer care, as Chairman of the company’s Scientific Advisory Board. In this role, Dr. Agus will serve as an adviser to the company, bringing 20 years of oncology experience and a commitment to innovation and cutting-edge technologies.
“David has spent his career on the frontlines working to advance treatments for patients diagnosed with cancer,” said Eric Lefkofsky, Co-founder and CEO of Tempus. “We are thrilled to bring his experience, insight and drive to Tempus as we work to revolutionize the way cancer treatment is delivered.”
“Tempus has created a platform and analytics engine unlike anything I’ve seen in the more than two decades I have spent studying cancer and treating patients,” said Dr. Agus. “Tempus is on the precipice of something truly unique, having built a system that not only allows researchers and physicians to gain a comprehensive understanding of patients on a molecular and clinical level, but also gets smarter with each patient that is added to the platform, to achieve the end goal of better patient care and outcome.”
Dr. Agus is currently a professor of medicine and engineering at the University of Southern California, where he leads USC’s Lawrence J. Ellison Institute for Transformative Medicine. He earned a bachelor’s degree from Princeton University, his medical degree from University of Pennsylvania’s School of Medicine and participated in a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center.
Tempus has recruited a world-class team of accomplished geneticists, computational biologists, data scientists and software engineers who have developed the software and analytic tools that form the foundation of an operating system to battle cancer. The company provides molecular sequencing and clinical analysis for top academic centers, hospital systems, associations, and healthcare providers such as Mayo Clinic, University of Pennsylvania’s Abramson Cancer Center, Northwestern’s Lurie Cancer Center, and the University of Michigan Comprehensive Cancer Center.
About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.
